FDA Grants 510(k) Clearance for Sonic Incytes' Velacur ONE
The launch of Velacur ONE™ marks a pivotal milestone for Sonic Incytes as we accelerate our US and global commercial expansion strategy.
Velacur ONE™ arrives at a critical time for improved non-invasive testing, following the recent FDA clearance of Rezdiffra—the first therapeutic for Metabolic dysfunction–associated steatohepatitis (MASH), a progressive and often underdiagnosed liver disease. In the U.S. alone, an estimated 100 million adults have Metabolic dysfunction–associated Steatotic Liver Disease (MASLD) 1, with 15–20 million of those affected by MASH 2. Yet, 90% of MASH cases remain undiagnosed 3. If left untreated, worsening MASH increases morbidity and may progress to severe complications, including cirrhosis, liver failure, liver cancer, and liver transplant 4,5. MASH remains challenging to diagnose effectively due to the limitations of existing non-invasive methods, especially those available at the point-of-care.
With the first therapeutic now available and more in the pipeline, clinicians need improved non-invasive tests to diagnose and monitor MASH at point-of-care 6. Current treatment guidelines for MASH recommend imaging-based elastography, such as Velacur™, to assess liver scarring (fibrosis) and fat content (steatosis). While ultrasound elastography is widely used, when it comes to treating patients with MASH, liver stiffness alone cannot be relied on to assess treatment response in the short term 7. The best predictor of treatment responses was a decrease in steatosis (identified as ≥30% reduction in MRI-PDFF) 8.
VDFF, Sonic Incytes' proprietary algorithm that received FDA clearance in 2024, demonstrates a strong correlation (r = 0.85) with MRI-PDFF—the gold standard for liver fat measurement—and achieves an outstanding accuracy (AUC) of 95% of patients with more than 5% MRI-PDFF, defining the presence of hepatic steatosis 9. Velacur ONE™ combines this technology with a refined user interface, including B-mode imaging—enabling 3–4x higher reimbursement than non-imaging elastography—and an AI-based organ overlay feature to aid in liver localization, making it the only point-of-care device that estimates both liver stiffness and attenuation that correlates to MRI-PDFF 10.
'The launch of Velacur ONE™ marks a pivotal milestone for Sonic Incytes as we accelerate our US and global commercial expansion strategy,' said Barry Allen, CEO of Sonic Incytes. 'This next-generation device enhances clinical utility and operational scalability, positioning us to better support the growing demand for accessible, non-invasive liver diagnostics and treatment, particularly in the management of MASLD and MASH at the point-of-care. '
About Sonic Incytes
Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur™ offers real-time, AI-guided quantification of the key markers for fatty liver disease: liver stiffness, attenuation and VDFF. With real-time results, a low up-front cost and AI guidance, Velacur™ makes liver imaging at the point-of-care affordable and accessible.
For more information, visit www.sonicincytes.com.
________________________________
1 American Liver Foundation. (2025, June). Nonalcoholic fatty liver disease (NAFLD). American Liver Foundation
2 Le P, Tatar M, Dasarathy S, et al. Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050. JAMA Netw Open. 2025;8(1):e2454707. doi:10.1001/jamanetworkopen.2024.54707
3 Fishman, J., Kim, Y., Charlton, M.R. et al. Estimation of the Eligible Population For Resmetirom Among Adults in the United States for Treatment of Non-Cirrhotic NASH with Moderate-to-Advanced Liver Fibrosis. Adv Ther 41, 4172–4190 (2024). https://doi.org/10.1007/s12325-024-02989-5
4 Friedman SL. Fat, fibrosis, and the future: navigating the maze of MASLD/MASH. J Clin Invest. 2025 Apr 1;135(7):e186418. doi: 10.1172/JCI186418. PMID: 40166940; PMCID: PMC11957683.
5 Fishman J, Alexander T, Kim Y, Kindt I, Mendez P. A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol. J Comp Eff Res. 2024 Oct;13(10):e240085. doi: 10.57264/cer-2024-0085. Epub 2024 Sep 20. PMID: 39301878; PMCID: PMC11426282.
6 Gbadamosi, S. O., Evans, K. A., Brady, B. L., & Hoovler, A. (2025). Noninvasive tests and diagnostic pathways to MASH diagnosis in the United States: a retrospective observational study. Journal of Medical Economics, 28 (1), 314–322. https://doi.org/10.1080/13696998.2025.2468582
7 Noureddin, M., Charlton, M. R., Harrison, S. A., Bansal, M. B., Alkhouri, N., Loomba, R., Sanyal, A. J., & Rinella, M. E. (2024). Expert panel recommendations: Practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis. Clinical Gastroenterology and Hepatology, 22(12), 2367–2377.
8 Chen VL, Morgan TR, Rotman Y, Patton HM, Cusi K, Kanwal F, Kim WR. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18. Erratum in: Hepatology. 2025 Apr 1;81(4):E133.
9 Honarvar, M., Lobo, J., Schneider, C., Klein, S., Smith, G. I., Loomba, R., Ramji, A., Hassanein, T., Yoshida, E. M., Pang, E., Curry, M. P., & Afdhal, N. H. (2024). Methods and validation of Velacur determined fat fraction in patients with MASLD. WFUMB Ultrasound Open, 2(2), Article 100061.
Expand
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
2 hours ago
- NBC News
FDA warns about unapproved thyroid pills — then says it'll 'ensure access' to them
An unusual about-face that played out at the Food and Drug Administration over the last week illustrated the power of the 'Make America Healthy Again' movement, particularly with its focus on 'natural' drugs. Last Thursday, the agency published a statement saying it had concerns about the safety and effectiveness of unapproved thyroid medications made from animal tissue after it received complaints from patients and reports of adverse events. As a result, the FDA said it had notified drugmakers of its 'intent to take action' against the products, but added that it wouldn't do so immediately to give patients time to switch medications. 'The agency urges patients taking these unapproved animal-derived thyroid medications to treat hypothyroidism to talk to their doctor,' it wrote. The statement in and of itself was nothing surprising. Warnings about unapproved drugs are standard fare for the FDA. What followed also wasn't unheard of: social media backlash. But on Wednesday evening, FDA Commissioner Marty Makary seemingly reversed course, writing in a post on X that the FDA was committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials. 'In the mean time, we will ensure access for all Americans,' he wrote. Five minutes later, Health Secretary Robert F. Kennedy Jr. responded. 'Love your approach of using gold standard science and common sense, @DrMarkaryFDA,' Kennedy wrote. So, what was this all about? Animal-derived thyroid pills The thyroid — a small, butterfly-shaped gland located at the front of the neck — helps regulate how the body uses energy by producing thyroid hormones. When it doesn't produce enough, it can lead to hypothyroidism, which can cause symptoms including unexplained weight gain, tiredness, sensitivity to cold, changes in menstrual cycles and symptoms of depression and anxiety, according to the Mayo Clinic. The condition is more common in women than men. The standard treatment is prescription thyroid hormone replacement therapy — basically, taking pills that contain the needed thyroid hormones. Typically one of two synthetic hormones, levothyroxine or liothyronine, or a combination of both, are prescribed. Some patients, however, turn to animal-derived thyroid pills either because they don't respond well to the synthetic versions or want to take something marketed as natural, said Dr. Michael Weintraub, an endocrinologist at NYU Langone Health in New York City. The pills — which aren't FDA-approved — are made from dried thyroid glands, usually from pigs, and are sold under brand names like Armour Thyroid, NP Thyroid, Nature-Thyroid and Natural Thyroid, according to the agency. About 1.5 million people in the U.S. were prescribed animal-derived thyroid pills in 2024, the FDA said. In the FDA statement warning against the animal-derived drugs, the agency said they may contain impurities that could result in infections and could also contain inconsistent levels of thyroid hormones, another risk for patients. Taking too much can cause unwanted effects, the FDA said, and too little could not be effective. The backlash In the days that followed the FDA's statement, patients and doctors took to social media to voice their opposition. 'BREAKING FDA set to BAN natural desiccated thyroid medications. Millions rely on these for hypothyroidism who don't respond well to synthetic thyroid pharmaceuticals,' read one post from Will Cole, a functional medicine doctor. 'Let your voice be heard. The FDA needs to change course on this one.' Dave Asprey, the founder of Bulletproof Coffee, a coffee and supplement brand, wrote: 'I found out I had very low thyroid levels in my mid-20s, and Hashimoto's. Normal synthetic thyroid drugs did not work. Natural thyroid extract worked very well and I have been taking it for more than 25 years without a problem.' Dr. Robert Malone — an anti-vaccine activist who was recently appointed by Kennedy to a vaccine advisory panel — called the decision 'terrible news — particularly for postmenopausal women.' He called on doctors and patients to contact the FDA in response. Andrew Nixon, a spokesperson for the Department of Health and Human Services, did not respond to a question about whether Makary's post on Wednesday was in response to social media backlash. When asked about whether the FDA would still take action against unapproved thyroid products, Nixon referred NBC News to the agency's statement last week, which said, 'FDA is not taking immediate action against manufacturers who make unapproved animal-derived thyroid medication to give patients time to transition to an FDA-approved medication to treat their hypothyroidism.' Nixon added that the agency 'will share additional information as it becomes available and as clinical trial results are released.' It's unclear which ongoing trials Makary and Nixon were referring to. lists a trial initiated by Walter Reed National Military Medical Center in 2012, but the trial's status is currently marked as 'unknown.' Allergan, the maker of Armour Thyroid, completed a trial in 2021 comparing its product to levothyroxine, a synthetic thyroid hormone. So, are these pills safe? Dr. Pieter Cohen, an associate professor of medicine at Harvard Medical School, said the FDA was correct to issue its initial warning about the thyroid pills, noting that the animal-derived pills aren't regulated by the agency and can pose significant risks. The FDA-approved synthetic versions usually replace one of two thyroid hormones: T4, the main hormone the thyroid produces, or T3, the active form of T4 that helps regulate energy and metabolism. Companies that make FDA-approved drugs must follow certain regulations, including consistent dosing. The animal-derived versions also contain the thyroid hormones, just like prescription medications, Cohen said, but because they're unregulated, the amount they contain can be all over the place. 'Getting too much or too little thyroid hormone has long-term health risks,' he said. 'If you take too much, it can damage your bones, it can damage your heart. If you take too little, if you're not getting enough, a number of problems can occur too, including mood problems, like depression.' Weintraub, of NYU Langone Health, said that tiny changes in thyroid hormone levels can have a big impact, so it's important to get the dosage right. He noted that pigs naturally have much higher levels of T3 than humans. 'It can lead to heart rhythm disturbances, which can be life-threatening. It can lead to bone degradation, which can lead to broken bones,' he said. Weintraub said he's had patients who took animal-derived thyroid pills who've had issues with sleeping, had sensitivity to heat or developed osteoporosis. Dr. Susan Spratt, an endocrinologist and senior medical director for the Population Health Management Office at Duke Health in North Carolina, however, said that it would be unfair for the FDA to 'suddenly yank' the animal-derived versions from the market 'without dedicated reasons that they are harmful.' Spratt said that the animal-derived pills have been around for decades as a prescribable drug. (Weintraub said the animal-derived drugs were 'grandfathered in,' meaning they were already on the market before current FDA standards for safety were put into place.) While Spratt said she prefers to prescribe the FDA-approved synthetic versions, the animal-derived versions offer an option for people who don't respond well to the synthetic ones. 'I would welcome NIH funding on why some patients don't feel as good on T4-only products,' she said. Weintraub said the synthetic versions don't 'necessarily help everyone's symptoms, but there's a more precise and safer way of treating that than resorting to a pig or cow thyroids.' He said patients who don't respond well to T4- or T3-only medications often do better on a combination of the two.
Axios
3 hours ago
- Axios
Colorado AG issues public advisory on kratom sales
The FDA is following Colorado's lead in cracking down on a potent compound found in kratom supplements: 7-hydroxymitragynine, or 7-OH. Why it matters: Products with 7-OH — which acts like an opioid and has been dubbed "legal morphine" by researchers — have surged in popularity. The big picture: In July, the FDA recommended more regulation of 7-OH products and warned consumers about their risks. Last month, the FDA also sent a letter to companies about the illegal marketing of 7-OH products, calling them potentially dangerous and unproven. The latest: Colorado Attorney General Phil Weiser issued a public advisory this week to alert consumers to "important new protections" related to kratom sales. "The law institutes new requirements for manufacturers, gives consumers new information about these products, and protects kids," Weiser said in a statement. Context: In May, state lawmakers approved a new law that toughens penalties for the sale of kratom by limiting it to those 21 and older and banning vape and candy-like products.
Business Wire
3 hours ago
- Business Wire
Veriheal Expands Patient Support Services With State-Compliant Medical Cannabis Letters
DENVER--(BUSINESS WIRE)--Veriheal, a leading health-tech company specializing in personalized cannabis access, announced this month the expansion of its services to include support beyond certification. The new offerings include state-compliant, physician-signed letters that provide documentation of lawful cannabis use by medical marijuana patients. Veriheal Expands Patient Support Services With State-Compliant Medical Cannabis Letters Veriheal's expanded suite includes medical cannabis letters of necessity and medical diagnosis summaries that confirm lawful marijuana use. These documents are designed to support patients through legal hurdles and assist with applications for employment, insurance, and public programs such as social services. This launch is the first in a series of services reflecting Veriheal's commitment to holistic patient support. The physician-signed letters aim to help patients confidently navigate complex systems while remaining compliant with both federal and state laws. Veriheal will continue the rollout later this year, addressing challenges of medical cannabis use that extend beyond card certification. 'Our patients deserve peace of mind when managing their health,' said Erik Smith, M.D., Medical Director at Veriheal. 'This launch is a foundational step in Veriheal's evolution from a certification provider to a long-term partner in wellness and advocacy.' Available now, patients can request letters to verify legal cannabis use for: Employment and conversations with Human Resources Communications with a parole officer or supervising authority Applications for social services and public programs Documentation of legal possession while driving or on person Supporting state disability paperwork Insurance reimbursement claims or appeals General support for travel or consulting with other medical professionals Each letter is signed by a licensed physician based on the patient's active medical cannabis certification. Patients without a medical cannabis card can access a bundled service to obtain certification and letters of medical necessity. The letters are available digitally on Veriheal's platform and can be requested directly from patients' user portal. For more information, visit About Veriheal Veriheal is a healthcare technology company that facilitates access to medical marijuana cards. As the largest facilitator in the nation, Veriheal advocates for patients and ensures safe access to regulated medical cannabis products. With a commitment to transparency, Veriheal connects patients and physicians through its proprietary, HIPAA-compliant platform. Visit for more information.
